ASH 2013: Dr. Wiestner Discusses Why Therapy in CLL Needs to be Individualized
Dr. Wiestner points out that the groundbreaking work of the late Dr. Hamblin on mutation status is now much nuanced.
What this new understanding demands is a different approach for every patient based on their biology and their personal preferences.
This is a future that I can buy into.
I will be continuing to publish interviews from both iwCLL and ASH and share my take on some of the important ASH papers.
This short post is brought to your from the free internet offered at the Athens airport as I start my long trip home after meeting with some other blood cancers advocates in Athens, and having an amazing time enjoying new Greek friends and and ancient Greek sites.
More on both soon.
Life is good.